Hologic acquires uterine fibroid system developer Interlace Medical
13 Jan 2011
Hologic, Inc. a developer of diagnostics, medical
imaging systems and surgical products for women's health has acquired
Interlace Medical, Inc. a developer and manufacturer of the MyoSure
hysteroscopic tissue removal system.
The purchase price for the transaction was $125 million in cash,
subject to adjustment, plus two annual contingent payments. The
contingent payments will be payable in cash and each will be
calculated as a multiple of the incremental revenue growth over the
Interlace's operations will be integrated within Hologic's GYN
Surgical Products division.
"The acquisition of Interlace is consistent with our strategy to
strengthen our leadership position in women's healthcare," said
Steve Williamson, Senior Vice President and General Manager, GYN
"MyoSure is an innovative technology that is designed to safely
and easily remove fibroids and polyps that plague millions of women.
This product is a natural extension of our industry-leading OB/GYN
product portfolio which now provides women with minimally invasive
treatment options from their child bearing years to menopause. The
strong clinical performance and ease of use of the MyoSure device
make it a natural fit with our NovaSure endometrial ablation and
Adiana permanent contraception product lines."
Interlace, a privately-held company headquartered in Framingham,
Massachusetts, USA, is dedicated to developing innovative
technologies to treat common gynaecological diseases for improved
patient outcomes while simplifying physician adoption and reducing
the cost of healthcare.
In the United States, there are approximately 5 million women
suffering from symptomatic fibroids or polyps who can be treated
with the MyoSure procedure. Symptomatic fibroids or polyps can be
debilitating and often are accompanied by heavy menstrual bleeding,
pelvic cramping and pain with periods.
The MyoSure system is a new and innovative treatment that is
designed to provide incision-less, fast and safe removal of
intracavitary fibroids and polyps and effective relief of the
associated abnormal uterine bleeding symptoms. It provides a
treatment option for women seeking to preserve uterine form and
The easy-to-use device is designed to provide gynaecologists with
confidence and control via a minimally-invasive care option for
their patients. Clinical studies show the efficacy rate for
hysteroscopic removal of fibroids is very high with close to 96
percent of patients receiving symptom resolution and less than 10
percent recurrence at five years.
"The Interlace acquisition
gives Hologic a minimally-invasive treatment option for uterine
fibroids and polyps," said Dr. Edward Evantash, Medical Director and
Vice President Medical Affairs. "Women with these uterine
abnormalities typically suffer from heavy periods, discomfort, and
infertility. The MyoSure system is designed to allow physicians to
remove these abnormalities safely and effectively with little to no
recovery time while preserving the uterus."
roll out physician training and education programs for MyoSure,
culminating in the full integration and promotion of the product in
"We are excited to be joining Hologic to build
upon the early success of MyoSure," said Bill Gruber, President and
CEO of Interlace. "Hologic has established itself as the leader in
women's health with best-in-class products, medical education, and
physician training, service and support capabilities. By joining
forces, we are confident we can give more women in need access to
the MyoSure treatment."